Haemodynamic profile of patients with end-stage liver disease

Cardiovascular Diseases and Liver Transplantation

Volumn , Issue , 2011, Pages 1-30

  Møller, Søren ^a   Henriksen, Jens H ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84879787314     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (169)

1. Iwakiri Y, Groszmann RJ. The hyperdynamic circulation of chronic liver diseases: from the patient to the molecule. Hepatology 2006;43(2 Suppl 1):S121-31.
2. Møller S, Henriksen JH. Cardiovascular complications of cirrhosis. Gut 2008;57(2):268-78.
3. Schrier RW, Arroyo V, Bernardi M, Epstein M, Henriksen JH, Rodés J. Peripheral artery vasodilatation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology 1988;5:1151-7.
4. Schrier RW. Renin-angiotensin in preascitic cirrhosis: evidence for primary peripheral arterial vasodilatation. Gastroenterology 1998;115(2):489-91.
5. Møller S, Bendtsen F, Henriksen JH. Vasoactive substances in the circulatory dysfunction of cirrhosis. Scand. J. Clin. Lab. Invest.2001;61(6):421-9.
6. Iwakiri Y. The molecules: mechanisms of arterial vasodilatation observed in the splanchnic and systemic circulation in portal hypertension. J. Clin. Gastroenterol. 2007;41(Suppl 3):S288-94.
7. Arroyo V, Fernandez J, Ginès P. Pathogenesis and treatment of hepatorenal syndrome. Semin. Liver Dis.2008;28(1):81-95.
8. Gerbes AL. The patient with refractory ascites. Best Pract. Res. Clin. Gastroenterol. 2007;21(3):551-60.
9. Ginès P, Schrier RW. Renal failure in cirrhosis. N. Engl. J. Med.2009;361(13):1279-90.
10. Witte CL, Witte MH. The portocardiorenal axis and refractory ascites: the underfilled cup runneth over. Hepatology 1989;10(1):114-16.
11. Alqahtani SA, Fouad TR, Lee SS. Cirrhotic cardiomyopathy. Semin. Liver. Dis. 2008;28(1):59-69.
12. Møller S, Krag A, Henriksen JH, Bendtsen F. Pathophysiological aspects of pulmonary complications of cirrhosis. Scand. J. Gastroenterol. 2007;42(4):419-27.
13. Henriksen JH, Fuglsang S, Bendtsen F, Christensen E, Møller S. Arterial compliance in patients with cirrhosis. High stroke volume/pulse pressure ratio as an index of elevated arterial compliance. Am. J. Physiol.2001;280:G584-94.
14. Llach J, Ginés P, Arroyo V, Rimola A, Titó L, Badalamenti S, et al. Prognostic value of arterial pressure, endogenous vasoactive systems, and renal function in cirrhotic patients admitted to the hospital for the treatment of ascites. Gastroenterology 1988;94:482-7.
15. Braillon A, Cales P, Valla D, Gaudy D, Geoffroy P, Lebrec D. Influence of the degree of liver failure on systemic and splanchnic haemodynamics and on response to propranolol in patients with cirrhosis. Gut 1986;27:1204-9.
16. Møller S. Systemic haemodynamics in cirrhosis and portal hypertension with focus on vasoactive substances and prognosis. Dan. Med. Bull. 1998;45(1):1-14.
17. Møller S, Hillingsø J, Christensen E, Henriksen JH. Arterial hypoxaemia in cirrhosis: fact or fiction? Gut 1998;42(6):868-74.
18. Hobolth L, Dümcke CW, Bendtsen F, Møller S. Determinants of the hyperdynamic circulation and central hypovolaemia in cirrhosis and portal hypertension. J. Hepatol. 2009;50:S80.
19. Møller S, Henriksen JH. The systemic circulation in cirrhosis. In: Ginès P, Arroyo V, Rodés J, Schrier RW, editors. Ascites and renal dysfunction in liver disease. 2nd edn. Malden: Blackwell; 2005; pp. 139-55.
20. Bernardi M, Fornalè L, Di Marco C, Trevisani F, Baraldini M, Gasbarrini A, et al. Hyperdynamic circulation of advanced cirrhosis: A re-appraisal based on posture-induced changes in hemodynamics. J. Hepatol.1995;22:309-18.
21. Laffi G, Barletta G, Lavilla G, Delbene R, Riccardi D, Ticali P, et al. Altered cardiovascular responsiveness to active tilting in nonalcoholic cirrhosis. Gastroenterology 1997;113:891-8.
22. Gentilini P, Romanelli RG, Laffi G, Barletta G, Del Bene R, Messeri G, et al. Cardiovascular and renal function in normotensive and hypertensive patients with compensated cirrhosis: effects of posture. J. Hepatol. 1999;30(4):632-8.
23. Møller S, Nørgaard A, Henriksen JH, Frandsen E, Bendtsen F. Effects of tilting on central hemodynamics and homeostatic mechanisms in cirrhosis. Hepatology 2004;40(4):811-19.
24. Brinch K, Møller S, Bendtsen F, Becker U, Henriksen JH. Plasma volume expansion by albumin in cirrhosis. Relation to blood volume distribution, arterial compliance and severity of disease. J. Hepatol. 2003;39(1):24-31.
25. Schrier RW. Water and sodium retention in edematous disorders: role of vasopressin and aldosterone. Am. J. Med.2006;119(7 Suppl 1):S47-53.
26. Møller S, Bendtsen F, Henriksen JH. Effect of volume expansion on systemic hemodynamics and central and arterial blood volume in cirrhosis. Gastroenterology 1995;109:1917-25.
27. Kiszka-Kanowitz M, Henriksen JH, Møller S, Bendtsen F. Blood volume distribution in patients with cirrhosis: aspects of the dual-head gamma-camera technique. J. Hepatol. 2001;35(5):605-12.
28. Møller S, Bendtsen F, Christensen E, Henriksen JH. Prognostic variables in patients with cirrhosis and oesophageal varices without prior bleeding. J. Hepatol. 1994;21:940-6.
29. Møller S, Henriksen JH. Cardiovascular dysfunction in cirrhosis. Pathophysiological evidence of a cirrhotic cardiomyopathy. Scand. J. Gastroenterol. 2001;36(8):785-94.
30. Bendtsen F, Henriksen JH, Sørensen TIA. Long-term effects of oral propranolol on splanchnic and systemic haemodynamics in patients with cirrhosis and oesophageal varices. Scand. J. Gastroenterol.1991;26:933-9.
31. Groszmann RJ. Vasodilatation and hyperdynamic circulatory state in chronic liver disease. In: Bosch J, Groszmann RJ, editors. Portal hypertension. Pathophysiology and treatment. 1st edn. Oxford: Blackwell; 1994; pp. 17-26.
32. Arroyo V, Colmenero J. Ascites and hepatorenal syndrome in cirrhosis: pathophysiological basis of therapy and current management. J. Hepatol. 2003;38 (Suppl 1):S69-89.
33. Møller S, Henriksen JH. Circulatory abnormalities in cirrhosis with focus on neurohumoral aspects. Semin. Nephrol. 1997;17(6):505-19.
34. Schrier RW, Ecder T. Unifying hypothesis of body fluid volume regulation: implications for cardiac failure and cirrhosis. Mt. Sinai J. Med. 2001;68(6):350-61.
35. Martin PY, Ginès P, Schrier RW. Mechanisms of disease: nitric oxide as a mediator of hemodynamic abnormalities and sodium and water retention in cirrhosis. N. Engl. J. Med.1998;339(8):533-41.
36. Wiest R, Groszmann RJ. The paradox of nitric oxide in cirrhosis and portal hypertension: too much, not enough. Hepatology 2002;35(2):478-91.
37. Møller S, Bendtsen F, Schifter S, Henriksen JH. Relation of calcitonin gene-related peptide to systemic vasodilatation and central hypovolaemia in cirrhosis. Scand. J. Gastroenterol.1996;31:928-33.
38. Hori N, Okanoue T, Sawa Y, Kashima K. Role of calcitonin gene-related peptide in the vascular system on the development of the hyperdynamic circulation in conscious cirrhotic rats. J. Hepatol. 1997;26:1111-19.
39. Guevara M, Ginès P, Jiménez W, Sort P, Fernández-Esparrach G, Escorsell A, et al. Increased adrenomedullin levels in cirrhosis: relationship with hemodynamic abnormalities and vasoconstrictor systems. Gastroenterology 1998;114:336-43.
40. Batkai S, Jarai Z, Wagner JA, Goparaju SK, Varga K, Liu J, et al. Endocannabinoids acting at vascular CB1 receptors mediate the vasodilated state in advanced liver cirrhosis. Nat. Med. 2001;7(7):827-32.
41. Moezi L, Gaskari SA, Lee SS. Endocannabinoids and liver disease. V. endocannabinoids as mediators of vascular and cardiac abnormalities in cirrhosis. Am. J. Physiol. Gastrointest. Liver Physiol. 2008;295(4):G649-53.
42. Ros J, Claria J, To-Figueras J, Planaguma A, Cejudo-Martin P, Fernandez-Varo G, et al. Endogenous cannabinoids: a new system involved in the homeostasis of arterial pressure in experimental cirrhosis in the rat. Gastroenterology 2002;122(1):85-93.
43. Farzaneh-Far R, Moore K. Nitric oxide and the liver. Liver 2001;21(3):161-74.
44. Rockey DC, Chung JJ. Reduced nitric oxide production by endothelial cells in cirrhotic rat liver: endothelial dysfunction in portal hypertension. Gastroenterology 1998;114:344-51.
45. McNaughton L, Puttagunta L, Martinez-Cuesta MA, Kneteman N, Mayers I, Moqbel R, et al. Distribution of nitric oxide synthase in normal and cirrhotic human liver. Proc. Natl. Acad. Sci. U S A 2002;99(26):17161-6.
46. Tazi KA, Barriere E, Moreau R, Heller J, Sogni P, Pateron D, et al. Role of shear stress in aortic eNOS up-regulation in rats with biliary cirrhosis. Gastroenterology 2002;122(7):1869-77.
47. Lee F-Y, Colombato LA, Albillos A, Groszmann RJ. N omega-nitro-L-arginine administration corrects peripheral vasodilatation and systemic capillary hypotension and ameliorates plasma volume expansion and sodium retention in portal hypertensive rats. Hepatology 1993;17:84-90.
48. Niederberger M, Martin P-Y, Ginès P, Morris K, Tsai P, Xu D-L, et al. Normalization of nitric oxide production corrects arterial vasodilation and hyperdynamic circulation in cirrhotic rats. Gastroenterology 1995;109:1624-30.
49. La Villa G, Barletta G, Pantaleo P, Del Bene R, Vizzutti F, Vecchiarino S, et al. Hemodynamic, renal, and endocrine effects of acute inhibition of nitric oxide synthase in compensated cirrhosis. Hepatology 2001;34(1):19-27.
50. Helmy A, Newby DE, Jalan R, Johnston NR, Hayes PC, Webb DJ. Nitric oxide mediates the reduced vasoconstrictor response to angiotensin II in patients with preascitic cirrhosis. J. Hepatol.2003;38(1):44-50.
51. Fernandez M, Mejias M, Angermayr B, Garcia-Pagan JC, Rodés J, Bosch J. Inhibition of VEGF receptor-2 decreases the development of hyperdynamic splanchnic circulation and portal-systemic collateral vessels in portal hypertensive rats. J. Hepatol. 2005;43(1):98-103.
52. Gupta S, Morgan TR, Gordan GS. Calcitonin gene-related peptide in hepatorenal syndrome. J. Clin. Gastroenterol.1992;14:122-6.
53. Bendtsen F, Schifter S, Henriksen JH. Increased circulating calcitonin gene-related peptide (CGRP) in cirrhosis. J. Hepatol.1991;12:118-23.
54. Møller S, Becker U, Schifter S, Abrahamsen J, Henriksen JH. Effect of oxygen inhalation on systemic, central, and splanchnic haemodynamics in cirrhosis. J. Hepatol.1996;25:316-28.
55. Henriksen JH, Møller S, Schifter S, Bendtsen F. Increased arterial compliance in decompensated cirrhosis. J. Hepatol. 1999;31(4):712-18.
56. Henriksen JH, Møller S, Schifter S, Abrahamsen J, Becker U. High arterial compliance in cirrhosis is related to elevated circulating calcitonin gene-related peptide (CGRP) and low adrenaline, but not to activated vasoconstrictor systems. Gut 2001;49:112-18.
57. Richards AM, Nicholls MG, Lewis L, Lainchbury JG. Adrenomedullin. Clin. Sci. 1996;91:3-16.
58. Fábrega E, Casafont F, Crespo J, de la Peña J, San Miguel G, de las Heras G, et al. Plasma adrenomedullin levels in patients with hepatic cirrhosis. Am. J. Gastroenterol.1997;92(10):1901-4.
59. Genesca J, Gonzalez A, Catalan R, Segura R, Martinez M, Esteban R, et al. Adrenomedullin, a vasodilator peptide implicated in hemodynamic alterations of liver cirrhosis: relationship to nitric oxide. Digest Dis. Sci.1999;44(2):372-6.
60. Heinemann A, Wachter CH, Fickert P, Trauner M, Stauber RE. Vasopressin reverses mesenteric hyperemia and vasoconstrictor hyporesponsiveness in anesthetized portal hypertensive rats. Hepatology 1998;28(3):646-54.
61. Newby DE, Jalan R, Masumori S, Hayes PC, Boon NA, Webb DJ. Peripheral vascular tone in patients with cirrhosis: role of the renin-angiotensin and sympathetic nervous systems. Cardiovasc. Res. 1998;38(1):221-8.
62. Bandi JC, Fernández M, Bernadich C, De Lacy AM, García-Pagán JC, Bosch J, et al. Hyperkinetic circulation and decreased sensitivity to vasoconstrictors following portacaval shunt in the rat. Effects of chronic nitric oxide inhibition. J. Hepatol. 1999;31(4):719-24.
63. Jaue DN, Ma ZH, Lee SS. Cardiac muscarinic receptor function in rats with cirrhotic cardiomyopathy. Hepatology 1997;25:1361-5.
64. Moreau R, Komaichi H, Kirstetter P, Ohsuga M, Cailmail S, Lebrec D. Altered control of vascular tone by adenosine triphosphate-sensitive potassium channels in rats with cirrhosis. Gastroenterology 1994;106:1016-23.
65. Heinemann A, Wachter CH, Holzer P, Fickert P, Stauber RE. Nitric oxide-dependent and -independent vascular hyporeactivity in mesenteric arteries of portal hypertensive rats. Br. J. Pharmacol.1997;121(5):1031-7.
66. Gerbes AL, Remien J, Jüngst D, Sauerbruch T, Paumgartner G. Evidence for down-regulation of beta-2-adrenoceptors in cirrhotic patients with severe ascites. Lancet 1986;1:1409-11.
67. Lee SS, Pak JM, Medlicott SM, Bomzon A. Vasodilatory responses of isolated arteries of cirrhotic rats. Clin. Sci.1995;89:227-32.
68. Helmy A, Jalan R, Newby DE, Hayes PC, Webb DJ. Role of angiotensin II in regulation of basal and sympathetically stimulated vascular tone in early and advanced cirrhosis. Gastroenterology 2000; 118(3):565-72.
69. Helmy A, Jalan R, Newby DE, Johnston NR, Hayes PC, Webb DJ. Altered peripheral vascular responses to exogenous and endogenous endothelin-1 in patients with well-compensated cirrhosis. Hepatology 2001;33(4):826-31.
70. Bosch J, Abraldes JG, Groszmann R. Current management of portal hypertension. J. Hepatol.2003;38:S54-68.
71. Rockey DC. Hepatic blood flow regulation by stellate cells in normal and injured liver. Semin. Liver Dis. 2001;21(3):337-49.
72. Schepke M, Werner E, Biecker E, Schiedermaier P, Heller J, Neef M, et al. Hemodynamic effects of the angiotensin II receptor antagonist irbesartan in patients with cirrhosis and portal hypertension. Gastroenterology 2001;121(2):389-95.
73. Kowalski HJ, Abelmann WH. The cardiac output at rest in Laennec's cirrhosis. J. Clin. Invest.1953;32:1025-33.
74. Møller S, Iversen JS, Henriksen JH, Bendtsen F. Reduced baroreflex sensitivity in alcoholic cirrhosis: relations to hemodynamics and humoral systems. Am J Physiol Heart Circ. Physiol.2007;292(6):H2966-72.
75. Møller S, Henriksen JH. Cirrhotic cardiomyopathy: a pathophysiological review of circulatory dysfunction in liver disease. Heart 2002;87(1):9-15.
76. Zambruni A, Trevisani F, Caraceni P, Bernardi M. Cardiac electrophysiological abnormalities in patients with cirrhosis. J. Hepatol. 2006;44:994-1002.
77. Bernardi M, Calandra S, Colantoni A, Trevisani F, Raimondo ML, Sica G, et al. Q-T interval prolongation in cirrhosis: prevalence, relationship with severity, and etiology of the disease and possible pathogenetic factors. Hepatology 1998;27:28-34.
78. Rabie RN, Cazzaniga M, Salerno F, Wong F. The use of E/A ratio as a predictor of outcome in cirrhotic patients treated with transjugular intrahepatic portosystemic shunt. Am. J. Gastroenterol. 2009;104(8):2458-66
79. Liu H, Gaskari SA, Lee SS. Cardiac and vascular changes in cirrhosis: pathogenic mechanisms. World J. Gastroentero. 2006;12:837-42.
80. Mani AR, Ippolito S, Ollosson R, Moore KP. Nitration of cardiac proteins is associated with abnormal cardiac chronotropic responses in rats with biliary cirrhosis. Hepatology 2006;43:847-56.
81. Wong F, Girgrah N, Graba J, Allidina Y, Liu P, Blendis L. The cardiac response to exercise in cirrhosis. Gut 2001;49(2):268-75.
82. Huonker M, Schumacher YO, Ochs A, Sorichter S, Keul J, Rössle M. Cardiac function and haemodynamics in alcoholic cirrhosis and effects of the transjugular intrahepatic portosystemic stent shunt. Gut 1999;44(5):743-8.
83. Merli M, Valeriano V, Funaro S, Attili AF, Masini A, Efrati C, et al. Modifications of cardiac function in cirrhotic patients treated with transjugular intrahepatic portosystemic shunt (TIPS). Am. J. Gastroenterol. 2002;97(1):142-8.
84. Ginès P, Uriz J, Calahorra B, Garcia-Tsao G, Kamath PS, Del Arbol LR, et al. Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosis. Gastroenterology 2002;123(6):1839-47.
85. Pozzi M, Carugo S, Boari G, Pecci V, de Ceglia S, Maggiolini S, et al. Evidence of functional and structural cardiac abnormalities in cirrhotic patients with and without ascites. Hepatology 1997;26(5):1131-7.
86. Torregrosa M, Aguade S, Dos L, Segura R, Gonzalez A, Evangelista A, et al. Cardiac alterations in cirrhosis: reversibility after liver transplantation. J. Hepatol. 2005;42(1):68-74.
87. Grose RD, Nolan J, Dillon JF, Errington M, Hannan WJ, Bouchier IAD, et al. Exercise-induced left ventricular dysfunction in alcoholic and non-alcoholic cirrhosis. J. Hepatol.1995;22:326-32.
88. Epstein SK, Ciubotaru RL, Zilberberg MD, Kaplan LM, Jacoby C, Freeman R, et al. Analysis of impaired exercise capacity in patients with cirrhosis. Dig. Dis. Sci. 1998;43(8):1701-7.
89. Myers RP, Lee SS. Cirrhotic cardiomyopathy and liver transplantation. Liver Transpl. 2000;6(4 Suppl 1):S44-52.
90. Pozzi M, Redaelli E, Ratti L, Poli G, Guidi C, Milanese M, et al. Time-course of diastolic dysfunction in different stages of chronic HCV related liver diseases. Minerva Gastroenterol. Dietol. 2005;51(2):179-86.
91. Gaskari SA, Honar H, Lee SS. Therapy insight: cirrhotic cardiomyopathy. Nat Clin Pract. Gastroenterol. Hepatol. 2006;3(6):329-37.
92. Finucci G, Desideri A, Sacerdoti D, Bolognesi M, Merkel C, Angeli P, et al. Left ventricular diastolic function in liver cirrhosis. Scand J Gastroenterol 1996;31:279-84.
93. Henriksen JH, Fuglsang S, Bendtsen F, Christensen E, Møller S. Dyssynchronous electrical and mechanical systole in patients with cirrhosis. J Hepatol 2002;36(4):513-20.
94. Henriksen JH, Bendtsen F, Hansen EF, Møller S. Acute non-selective beta-adrenergic blockade reduces prolonged frequency-adjusted Q-T interval (QTc) in patients with cirrhosis. J. Hepatol.2004;40(2):239-46.
95. Henriksen JH, Gøetze JP, Fuglsang S, Christensen E, Bendtsen F, Møller S. Increased circulating pro-brain natriuretic peptide (proBNP) and brain natriuretic peptide (BNP) in patients with cirrhosis: relation to cardiovascular dysfunction and severity of disease. Gut 2003;52(10):1511-17.
96. Genovesi S, Prata Pizzala DM, Pozzi M, Ratti L, Milanese M, Pieruzzi F, et al. QT interval prolongation and decreased heart rate variability in cirrhotic patients: relevance of hepatic venous pressure gradient and serum calcium. Clin. Sci. (Lond) 2009;116(12):851-9.
97. Mohamed R, Forsey PR, Davies MK, Neuberger JM. Effect of liver transplantation on QT interval prolongation and autonomic dysfunction in end-stage liver disease. Hepatology 1996;23:1128-34.
98. Maroto A, Ginès P, Arroyo V, Ginès A, Saló J, Clària J, et al. Brachial and femoral artery blood flow in cirrhosis : relationship to kidney dysfunction. Hepatology 1993;17:788-93.
99. Luca A, García-Pagán JC, Feu F, Lopez-Talavera JC, Fernández M, Bru C, et al. Noninvasive measurement of femoral blood flow and portal pressure response to propranolol in patients with cirrhosis. Hepatology 1995;21:83-8.
100. Campillo B, Chabrier PE, Pelle G, Sediame S, Atlan G, Fouet P, et al. Inhibition of nitric oxide synthesis in the forearm arterial bed of patients with advanced cirrhosis. Hepatology 1995;22:1423-9.
101. Ferguson JW, Dover A, Chia S, Cruden N, Hayes PC, Newby D. Inducible nitric oxide synthase activity contributes to the regulation of peripheral vascular tone in patients with cirrhosis and ascites. Gut 2005;55(4):542-6.
102. Carella M, Hunter JO, Fazio S, Del Piano C, Bartoli GC. Capillary blood flow to the skin of forearm in cirrhosis. Angiology 1992;43:969-74.
103. Hadengue A, Moreau R, Gaudin C, Bacq Y, Champigneulle B, Lebrec D. Total effective vascular compliance in patients with cirrhosis: a study of the response to acute blood volume expansion. Hepatology 1992;15:809-15.
104. Andreu V, Perello A, Moitinho E, Escorsell A, García-Pagán JC, Bosch J, et al. Total effective vascular compliance in patients with cirrhosis. Effects of propranolol. J. Hepatol. 2002;36(3):356-61.
105. Møller S, Gulberg V, Becker U, Gerbes AL, Henriksen JH. Elevated arterial compliance in patients with cirrhosis is not related to arterial endothelin-1. Scand J. Gastroenterol. 2002;37(9):1064-9.
106. Møller S, Hansen EF, Becker U, Brinch K, Henriksen JH, Bendtsen F. Central and systemic haemodynamic effects of terlipressin in portal hypertensive patients. Liver 2000;20(1):51-9.
107. Rowell LB. Human cardiovascular control. Oxford: Oxford University Press; 1993.
108. Hendrickse MT, Triger DR. Vagal dysfunction and impaired urinary sodium and water excretion in cirrhosis. Am. J. Gastroenterol. 1994;89(5):750-7.
109. Trevisani F, Sica G, Mainquà P, Santese G, De Notariis S, Caraceni P, et al. Autonomic dysfunction and hyperdynamic circulation in cirrhosis with ascites. Hepatology 1999;30(6):1387-92.
110. Rangari M, Sinha S, Kapoor D, Mohan JC, Sarin SK. Prevalence of autonomic dysfunction in cirrhotic and noncirrhotic portal hypertension. Am. J. Gastroenterol. 2002;97(3):707-13.
111. Mani AR, Montagnese S, Jackson CD, Jenkins CW, Head IM, Stephens RC, et al. Decreased heart rate variability in patients with cirrhosis relates to the presence and severity of hepatic encephalopathy. Am. J. Physiol. Gastrointest Liver Physiol. 2009;296(2):G330-8.
112. Dillon JF, Nolan J, Thomas H, Williams BC, Neilson JMM, Bouchier IAD, et al. The correction of autonomic dysfunction in cirrhosis by captopril. J. Hepatol.1997;26:331-5.
113. Ates F, Topal E, Kosar F, Karincaoglu M, Yildirim B, Aksoy Y, et al. The relationship of heart rate variability with severity and prognosis of cirrhosis. Dig. Dis. Sci.2006;51(9):1614-8.
114. Barron HV, Alam I, Lesh MD, Strunk A, Bass NM. Autonomic nervous system tone measured by baroreflex sensitivity is depressed in patients with end-stage liver disease. Am. J. Gastroenterol. 1999;94(4):986-9.
115. Bernardi M, Rubboli A, Trevisani F, Cancellieri C, Ligabue A, Baradini M, et al. Reduced cardiovascular responsiveness to exercise-induced sympathoadrenergic stimulation in patients with cirrhosis. J. Hepatol.1991;12:207-16.
116. Villa GL, Barletta G, Romanelli RG, Laffi G, Del Bene R, Vizzutti F, et al. Cardiovascular effects of canrenone in patients with preascitic cirrhosis. Hepatology 2002;35(6):1441-8.
117. MacGilchrist AJ, Sumner D, Reid JL. Impaired pressor reactivity in cirrhosis: evidence for a peripheral vascular defect. Hepatology 1991;13:689-94.
118. Bolognesi M, Sacerdoti D, Di Pascoli M, Angeli P, Quarta S, Sticca A, et al. Haeme oxygenase mediates hyporeactivity to phenylephrine in the mesenteric vessels of cirrhotic rats with ascites. Gut 2005;54(11):1630-6.
119. Ferlitsch A, Pleiner J, Mittermayer F, Schaller G, Homoncik M, Peck-Radosavljevic M, et al. Vasoconstrictor hyporeactivity can be reversed by antioxidants in patients with advanced alcoholic cirrhosis of the liver and ascites. Crit. Care Med. 2005;33(9):2028-33.
120. Tripathi D, Therapondos G, Ferguson JW, Newby DE, Webb DJ, Hayes PC. Endothelin-1 contributes to maintenance of systemic but not portal haemodynamics in patients with early cirrhosis: a randomised controlled trial. Gut 2006;55(9):1290-5.
121. Møller S, Wiinberg N, Henriksen JH. Noninvasive 24-hour ambulatory arterial blood pressure monitoring in cirrhosis. Hepatology 1995;22:88-95.
122. Veglio F, Melchio R, Calva S, Rabbia F, Gallo V, Melino P, et al. Noninvasive assessment of spontaneous baroreflex sensitivity in patients with liver cirrhosis. Liver 1998;18(6):420-6.
123. Laffi G, Lagi A, Cipriani M, Barletta G, Bernardi L, Fattorini L, et al. Impaired cardiovascular autonomic response to passive tilting in cirrhosis with ascites. Hepatology 1996;24:1063-7.
124. Lazzeri C, Lavilla G, Laffi G, Vecchiarino S, Gambilonghi F, Gentilini P, et al. Autonomic regulation of heart rate and QT interval in nonalcoholic cirrhosis with ascites. Digestion 1997;58:580-6.
125. Hansen S, Møller S, Bendtsen F, Jensen G, Henriksen JH. Diurnal variation and dispersion in QT interval in cirrhosis: relation to haemodynamic changes. J. Hepatol. 2007;47(3):373-80.
126. Dumcke CW, Møller S. Autonomic dysfunction in cirrhosis and portal hypertension. Scand. J. Clin. Lab. Invest.2008;25:1-11.
127. Henriksen JH, Møller S. Hypertension and liver disease. Curr. Hypertens. Rep. 2004;6(6):453-61.
128. Arroyo V, Terra C, Ginès P. New treatments of hepatorenal syndrome. Semin. Liver Dis. 2006;26(3):254-64.
129. Ruiz-del-Arbol L, Monescillo A, Arocena C, Valer P, Ginès P, Moreira V, et al. Circulatory function and hepatorenal syndrome in cirrhosis. Hepatology 2005;42:439-47.
130. Gonzàlez-Abraldes J, Albillos A, Bañares R, del Arbol LR, Moitinho E, Rodríguez C, et al. Randomized comparison of long-term losartan versus propranolol in lowering portal pressure in cirrhosis. Gastroenterology 2001;121(2):382-8.
131. Salerno F, Gerbes A, Ginès P, Wong F, Arroyo V. Diagnosis, prevention and treatment of the hepatorenal syndrome in cirrhosis. Gut 2007;56:1310-8.
132. Krag A, Bendtsen F, Henriksen JH, Møller S. Low cardiac output predicts development of hepatorenal syndrome and survival in patients with cirrhosis and ascites. Gut 2010;59(1):105-10.
133. Ruiz-del-Arbol L, Urman J, Fernandez J, Gonzalez M, Navasa M, Monescillo A, et al. Systemic, renal, and hepatic hemodynamic derangement in cirrhotic patients with spontaneous bacterial peritonitis. Hepatology 2003;38(5):1210-18.
134. Hervé P, Lebrec D, Brenot F, Simonneau G, Humbert M, Sitbon O, et al. Pulmonary vascular disorders in portal hypertension. Eur. Resp. J.1998;11(5):1153-66.
135. Agusti AGN, Roca J, Rodriguez-Roisin R. Mechanisms of gas exchange impairment in patients with liver cirrhosis. Clin. Chest Med. 1996;17(1):49-66.
136. Krowka MJ. Hepatopulmonary syndromes. Gut 2000;46(1):1-4.
137. Fallon MB, Abrams GA. Pulmonary dysfunction in chronic liver disease. Hepatology 2000;32(4 Pt 1):859-65.
138. Söderman C, Juhlin-Dannfelt A, Lagerstrand L, Eriksson LS. Ventilation-perfusion relationships and central haemodynamics in patients with cirrhosis. Effects of a somatostatin analogue. J. Hepatol. 1994;21:52-7.
139. Abrams GA, Nanda NC, Dubovsky EV, Krowka MJ, Fallon MB. Use of macroaggregated albumin lung perfusion scan to diagnose hepatopulmonary syndrome: a new approach. Gastroenterology 1998;114:305-10.
140. Rodríguez-Roisin R, Agustí A, Roca J. The hepatopulmonary syndrome: new name, old complexities. Thorax. 1992;47:897-902.
141. Krowka MJ, Cortese DA. Hepatopulmonary syndrome: current concepts in diagnostic and therapeutic considerations. Chest 1994;105:1528-37.
142. Fallon MB, Abrams GA, Luo B, Hou ZY, Dai J, Ku DD. The role of endothelial nitric oxide synthase in the pathogenesis of a rat model of hepatopulmonary syndrome. Gastroenterology 1997;113:606-14.
143. Luo B, Liu L, Tang L, Zhang J, Stockard CR, Grizzle WE, et al. Increased pulmonary vascular endothelin B receptor expression and responsiveness to endothelin-1 in cirrhotic and portal hypertensive rats: a potential mechanism in experimental hepatopulmonary syndrome. J. Hepatol. 2003;38(5):556-63.
144. Söderman C, Leone A, Furst V, Persson MG. Endogenous nitric oxide in exhaled air from patients with liver cirrhosis. Scand. J. Gastroenterol.1997;32:591-7.
145. Rolla G, Brussino L, Colagrande P, Dutto L, Polizzi S, Scappaticci E, et al. Exhaled nitric oxide and oxygenation abnormalities in hepatic cirrhosis. Hepatology 1997;26:842-7.
146. Meyers C, Low L, Kaufman L, Druger G, Wong LL. Trendelenburg positioning and continuous lateral rotation improve oxygenation in hepatopulmonary syndrome after liver transplantation. Liver Transpl. Surg..1998;4(6):510-12.
147. Martínez GP, Barberà JA, Visa J, Rimola A, Paré JC, Roca J, et al. Hepatopulmonary syndrome in candidates for liver transplantation. J. Hepatol. 2001;34(5):651-7.
148. Allgaier HP, Haag K, Ochs A, Hauenstein KH, Jeserich M, Krause T, et al. Hepatopulmonary syndrome: successful treatment by transjugular intrahepatic portosystemic stent-shunt (TIPS). J Hepatol 1995;23:102.
149. Riegler JL, Lang KA, Johnson SP, Westerman JH. Transjugular intrahepatic portosystemic shunt improves oxygenation in hepatopulmonary syndrome. Gastroenterology 1995;109:978-83.
150. Thorens JB, Junod AF. Hypoxaemia and liver cirrhosis: a new argument in favour of a ?diffusion-perfusion defect{norm of matrix}. Eur Resp J 1992;5(16):754-6.
151. Rodríguez-Roisin R, Krowka MJ. Is severe arterial hypoxaemia due to hepatic disease an indication for liver transplantation? A new therapeutic approach. Eur. Resp. J. 1994;7:839-42.
152. Schenk P, Fuhrmann V, Madl C, Funk G, Lehr S, Kandel O, et al. Hepatopulmonary syndrome: prevalence and predictive value of various cut offs for arterial oxygenation and their clinical consequences. Gut 2002;51(6):853-9.
153. Krowka MJ. Hepatopulmonary syndrome versus portopulmonary hypertension: distinctions and dilemmas. Hepatology 1997;25:1282-4.
154. Cotes JE. Lung function. Assessment and application in medicine. 5th edn. Oxford: Blackwell; 1993.
155. Møller S, Burchardt H, Ogard CG, Schiodt FV, Lund JO. Pulmonary blood volume and transit time in cirrhosis: relation to lung function. Liver Int. 2006;26(9):1072-8.
156. Degano B, Mittaine M, Guénard H, Rami J, Garcia G, Kamar N, et al. Nitric oxide and carbon monoxide lung transfer in patients with advanced liver cirrhosis. J. Appl. Physiol. 2009;107(1):139-43.
157. Hadengue A, Kamal KB, Lebrec D, Benhamou JP. Pulmonary hypertension complicating portal hypertension: prevalence and relation to splanchnic hemodynamics. Gastroenterology 1991;100:520-8.
158. Katsuta Y, Zhang XJ, Kato Y, Shimizu S, Komeichi K, Ohsuga M, et al. Hemodynamic features and impaired arterial oxygenation in patients with portopulmonary hypertension. Hepatol. Res. 2005;32:79-88.
159. Rodríguez-Roisin R, Krowka MJ, Hervé P, Fallon MB. Pulmonary-hepatic vascular disorders (PHD). Eur Respir J 2004;24(5):861-80.
160. Kuntzen C, Gülberg V, Gerbes AL. Use of a mixed endothelin receptor antagonist in portopulmonary hypertension: a safe and effective therapy? Gastroenterology 2005;128(1):164-8.
161. Hoeper MM, Halank M, Marx C, Hoeffken G, Seyfarth HJ, Schauer J, et al. Bosentan therapy for portopulmonary hypertension. Eur. Respir. J. 2005;25(3):502-8.
162. Almdal T, Schroeder T, Ranek L. Cerebral blood flow and liver function in patients with encephalopathy due to acute and chronic liver diseases. Scand. J. Gastroenterol. 1989;24:299-303.
163. Larsen FS, Olsen KS, Ejlersen E, Hansen BA, Paulson OB, Knudsen GM. Cerebral blood flow autoregulation and transcranial Doppler sonography in patients with cirrhosis. Hepatology 1995;22:730-6.
164. Ede RJ, Gimson AES, Bihari D, Williams R. Controlled hyperventilation in the prevention of cerebral oedema in fulminant hepatic failure. J Hepatol 1986;2:43-51.
165. Larsen FS, Knudsen GM, Hansen BA. Pathophysiological changes in cerebral circulation, oxidative metabolism and blood-brain barrier in patients with acute liver failure. Tailored cerebral oxygen utilization. J. Hepatol.1997;27(1):231-8.
166. Lagi A, La Villa G, Barletta G, Cencetti S, Bacalli S, Cipriani M, et al. Cerebral autoregulation in patients with cirrhosis and ascites. A transcranial Doppler study. J. Hepatol. 1997;27:114-20.
167. Dam M, Burra P, Tedeschi U, Cagnin A, Chierichetti F, Ermani M, et al. Regional cerebral blood flow changes in patients with cirrhosis assessed with Tc-99m-HM-PAO single-photon emission computed tomography: effect of liver transplantation. J. Hepatol.1998;29(1):78-84.
168. Jalan R, Newby DE, Damink SW, Redhead DN, Hayes PC, Lee A. Acute changes in cerebral blood flow and metabolism during portasystemic shunting. Liver Transpl 2001;7(3):274-8.
169. Ring-Larsen H. Renal blood. Scand. J. Clin. Lab. Invest. 1977;37:635-42